Why biopharma industry is experiencing a talent crunch, HR News, ETHRWorld
hr.economictimes.indiatimes.com | www.ETHRWorld.com
Highlights
- India’s bioeconomy is estimated to have crossed the $92 billion mark by value in the year 2022.
- As per Cytiva’s global survey findings, there has been a decline in the overall resilience of the talent pool, with the score falling from 6.27 in 2021 to 5.60 in 2023.
India’s biotechnology industry is on a rising stage. It has become the 3rd largest destination for biotechnology in Asia Pacific. India’s bioeconomy is estimated to have crossed the $92 billion mark by value in the year 2022, and is now forecasted to reach $150 billion by 2025, and $300 billion by 2030.
But beneath this growth lies a lurking shadow – a talent shortage threatening to dim the industry’s bright future. Even Cytiva‘s Global Biopharma Resilience Index paints a stark picture, highlighting a critical skills gap as a major roadblock for India’s biotech aspirations.
The talent crunch manifests in various ways. A significant portion of the current workforce lacks specialised skill sets required for high-end research and development activities….?php>?=$v?>?php>
Click Here to Read more /Source link